4//SEC Filing
Perry Andrew 4
Accession 0001562180-22-000308
CIK 0001560241other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:25 PM ET
Size
11.2 KB
Accession
0001562180-22-000308
Insider Transaction Report
Form 4
Perry Andrew
Chief Commercial Officer
Transactions
- Award
Common Stock
2022-01-03+6,000→ 6,020 total - Award
Stock Options (Right to buy)
2022-01-03+26,500→ 26,500 totalExercise: $10.69Exp: 2032-01-03→ Common Stock (26,500 underlying)
Footnotes (4)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 20 shares of common stock; and (ii) 6,000 RSUs from award granted on January 3, 2022.
- [F4]The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Documents
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001877793
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:25 PM ET
- Size
- 11.2 KB